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Background In high-income countries, administration of antenatal steroids is
standard care for women with anticipated preterm labour.
However, although 41 million deaths due to preterm birth occur
annually, antenatal steroids are not routine practice in low-income
countries where most of these deaths occur.
Objectives To review the evidence for and estimate the effect on cause-specific
neonatal mortality of administration of antenatal steroids to women
with anticipated preterm labour, with additional analysis for the
effect in low- and middle-income countries.
Methods We conducted systematic reviews using standardized abstraction
forms. Quality of evidence was assessed using an adapted GRADE
approach. Existing meta-analyses were reviewed for relevance to
low/middle-income countries, and new meta-analysis was
performed.
Results We identified 44 studies, including 18 randomised control trials
(RCTs) (14 in high-income countries) in a Cochrane meta-analysis,
which suggested that antenatal steroids decrease neonatal mortality
among preterm infants (<36 weeks gestation) by 31% [relative risk
(RR)¼0.69; 95% confidence interval (CI) 0.58–0.81]. Our new
meta-analysis of four RCTs from middle-income countries suggests
53% mortality reduction (RR¼0.47; 95% CI 0.35–0.64) and 37%
morbidity reduction (RR¼0.63; 95% CI 0.49–0.81). Observational
study mortality data were consistent. The control group in these
equivalent studies was routine care (ventilation and, in many
cases, surfactant). In low-income countries, many preterm babies
currently receive little or no medical care. It is plausible that ante-
natal steroids may be of even greater effect when tested in these
settings.
Conclusions Based on high-grade evidence, antenatal steroid therapy is very
effective in preventing neonatal mortality and morbidity, yet
remains at low coverage in low/middle-income countries. If fully
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i122scaled up, this intervention could save up to 500000 neonatal lives
annually.
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Background
Every year,  4 million newborns die, and the leading
cause of death is direct preterm complications
accounting for 41 million deaths.
1 The most
common cause of deaths among preterm babies is
respiratory distress syndrome (RDS), an acute lung
disease related to immaturity of the lungs and, spe-
cifically, surfactant deficiency.
2 The incidence and
severity of RDS show an inverse relationship with
gestational age.
3–6 In high-income countries, most
babies 425 weeks gestation now survive.
7 In many
low-income countries, even moderately preterm
babies have high mortality rates—for example, in a
hospital in Dhaka, capital of Bangladesh, babies
born under 32 weeks of gestation had a 79% mortality
rate.
8 We use the World Bank definition of high-,
low- and middle-income countries.
9
Antenatal steroid treatment for women who are at
risk of preterm delivery has emerged as the most
effective intervention for the prevention of RDS, redu-
cing early neonatal mortality and morbidity.
10 Most
glucocorticoid hormones, natural and artificial, are
capable of crossing the placenta and trigger the
maturational process that leads to the production
and release of surfactant into the alveoli of the
foetal lung.
11–13 In 1969, Liggins
14 employed
b-methasone in the first clinical trial.
Given the evidence of benefit, antenatal steroid
treatment is now considered standard practice, and
in high-income countries, litigation is likely if antena-
tal steroids are not given when indicated.
15 In
high-income countries, coverage remained low for a
decade or so after clear evidence of effectiveness was
available, but following the NIH Consensus Statement
in 1994,
15 there has been almost universal uptake
in North America and Western Europe. As a result,
the profile of RDS incidence and severity in
high-income countries has altered allowing wider
use of non-invasive ventilation and continuous
airway pressure ventilation, reducing damage to the
lungs.
16
Antenatal steroid administration has been identified
as an essential and feasible intervention that could
beof enormous public health benefit in low/middle-
income countries where preterm birth is more
common, yet adequate neonatal care is often unavail-
able. For over half of the world’s births,ventilator sup-
port for RDS is very unlikely. To date, no systematic
reviews have focused on the potential benefit of ante-
natal steroid therapy in these settings.
Objective
The objective of the present study was to review the
evidence globally for and estimate the effect on neo-
natal mortality due to preterm birth complications of
antenatal steroid administration to women before
anticipated preterm labour, compared with placebo
or no treatment, with specific focus on variation on
the effect size in low- and middle-income countries.
Methods
Searches
Systematic searches of electronic databases were
undertaken including Cochrane Libraries, PubMed,
LILACS, African Medicus, EMRO, all World Health
Organization Regional Databases and publications in
any language (Figure 1). Online searches of major
conference proceedings were also conducted in order
to identify unpublished literature. The key search
terms were Steroid antenatal, newborn steroids, RDS new-
born steroids, Antenatal steroids, newborn steroids, RDS new-
born steroids and prenatal steroids. The systematic
searches were for studies published between January
1970 and September 2009. After initial screening of
titles and abstracts, we reviewed full-text publications
of possible studies.
Inclusion/exclusion criteria, abstraction
We applied the PICO format (Patient, Intervention,
Comparison and Outcome) to define the studies to
be included as follows. The population of interest was
neonates, and the intervention being studied was
administration of corticosteroids to women in
pretem labour. We included randomized controlled
trials or observational studies, where antenatal ster-
oids were given as therapy in premature labour and
where birth occurred between 24 h and 7 days after
treatment. All included studies incorporated a placebo
or a suitable control group that was similar to the
experimental group except that it did not receive
antenatal steroids. Studies were included if antenatal
steroids were given alone or in combination with anti-
biotics and surfactants. In trials including women
with multiple pregnancies, the number of babies
was used as the denominator for neonatal outcomes.
We sought to identify randomized controlled trials,
but due to lack of such studies, especially in
low-income settings, we also reviewed observational
studies fitting the above criteria.
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due to complications of preterm birth as used in
International Classification of Disease (ICD) version 10
and for global estimates for neonatal mortality; and
(ii) serious neonatal morbidity related to prematurity
(RDS and necrotizing enterocolitis). Preterm birth
(<37 weeks completed gestational age) is not consid-
ered a cause of death in ICD. Deaths are classified as
due to preterm birth if subsequent to specific
complications of preterm birth (such as RDS) or
‘extreme prematurity’ (<32 weeks gestation).
All studies, which met the inclusion criteria, were
abstracted onto a standardized form. We abstracted
key variables with regard to the study identifiers
and context, study design and limitations, interven-
tion specifics and outcome effects (Supplementary
Table 1). We assessed the quality of each of these
studies using a standard approach developed by the
Figure 1 Synthesis of study identification in review of the effects of antenatal corticosteroids for the treatment of RDS
morbidity and mortality in preterm labour. Bold/italic text shows new meta-analysis undertaken until May 2009
Table 1 RCTs from middle-income countries comparing administration of antenatal steroids for preterm labour with
placebo
No. Reference Country Case definition (drug used) Number of events in total
Effect size RR
(95% CI)
Intervention
group
Control
group
1 Amorim et al.
31,a Brazil All women with singleton live fetus,
26–34 weeks and severe
pre-eclampsia (Betamethasone)
14 in 100 28 in 100 0.50 (0.28–0.89)
2 Dexiprom, 1999
a South Africa Women with preterm rupture of
membranes or estimated fetal
weight 1000–2000g when going
into labour (Dexamethasone)
4 in 105 8 in 101 0.48 (0.15–1.55)
3 Qublan et al.
33,a Jordan Women with singleton pregnancies
and preterm rupture of mem-
branes (Dexamethasone)
19 in 70 39 in 65 0.45 (0.29–0.70)
4 Fekih et al.
34,a Tunisia Women in Preterm
labour (Betamethasone)
9 in 63 21 in 68 0.46 (0.23–0.93)
aIncluded in Cochrane review
10; RCT: randomised control trial; RR: relative risk.
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based on an adaptation of the GRADE approach.
17
Analysis and summary measures
We planned a priori to conduct three meta-analyses,
two for mortality outcomes (one with RCT as input
and one with observational studies) and one for mor-
bidity outcomes (RCT only). We also planned to
undertake additional sensitivity analysis to examine
bias that may be introduced by excluding certain
studies not meeting our criteria. We conducted all
meta-analysis using STATA version 10.0 statistical
software
18 and report the Mantel–Haenszel pooled rel-
ative risk and corresponding 95% confidence interval
(CI). Heterogeneity between studies was summarized
using the I
2 statistic. If this statistic was <10%, then a
random effects analysis was performed as opposed to
fixed effects. We summarized the overall quality of
evidence for each outcome and each data input type
using an adapted version of the GRADE protocol
table.
17
We conducted meta-analyses restricted to studies
performed in middle-income countries to assess the
effect of antenatal steroid administration on neonatal
mortality and morbidity in such settings. We also
reviewed the Cochrane neonatal mortality
meta-analysis for high-income settings taking account
of time period. In addition, we conducted sensitivity
meta-analyses for the studies included in the
Cochrane but including two of the studies that had
been excluded.
Results
We identified 1412 titles for screening (Figure 1) and
reviewed the full text of 212 papers. Of these, 40 were
not studies, 36 had no comparison group and 94 did
not report on mortality or serious morbidity. A total of
42 papers were included in the final database
(Supplementary Table). We identified 20 RCTs that
reported data on cause-specific mortality of which
18
14,19–35 had been included in the Cochrane review.
We excluded two studies
36,37 for similar reasons to
those given in the recent Cochrane, i.e. 420% post
randomization exclusions. The remaining trials had
few limitations. The majority (13) were
placebo-controlled, usually with normal saline injec-
tion. For the remainder, the control group received
management according to the local standard practice.
In around half of the studies (eight), randomization
was well described and was adequately concealed, but
for 10 studies, the randomization methods were not
clearly described. In web table, we summarize the
details of these studies and assess the quality of each.
Although 18 RCTs were identified, only four were
from middle-income countries: Brazil,
32 South
Africa,
33 Jordan
34 and Tunisia.
35 As we were specifi-
cally interested in evidence from low- and
middle-income countries, we also sought observa-
tional studies from such settings. Two observational
studies, reporting the effect of antenatal steroids on
neonatal deaths among preterm infants, were identi-
fied from Iran
38 (RR¼0.39; 95% CI 0.18–0.84; 282
babies) and Brazil
39 (RR¼0.61; 95% CI 0.43–0.85;
410 babies). No studies were identified from
low-income countries. The only African study was
from South Africa, and no studies were identified
form South Asia, where around half of newborn
deaths are found.
Definition of the intervention
Who for?
This intervention is for women in preterm labour or at
high risk of preterm labour (e.g. with pre-eclampsia
and planning preterm caesarean section). Studies
included the gestational age at administration, ran-
ging from 23 weeks to 36 weeks, and women with
both spontaneous preterm labour or planned preterm
delivery. Figure 2 shows the variation of effect on
Figure 2 The variation of mortality effect according to gestational age of administration of antenatal steroids to women in
preterm labour compared with placebo. Figure created using data from
10 showing distinct risk by gestational age bands (i.e.
not cumulative risk). For gestational age of 436 weeks, the 95% CI is not shown (RR¼2.2; 0.79, 8.96; 896 babies)
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Between 31 weeks and 36 weeks of gestational age,
there is430% reduction in mortality. Before 30 weeks,
the evidence for an effect is weaker and the benefit
may be smaller. After 36 weeks of gestation, there is
no evidence of a mortality benefit. Hence, this inter-
vention has an effect only on preterm babies, is
mediated through a reduction in preterm specific
respiratory complications and can be assumed to
relate to the category of direct preterm deaths used
in ICD and in LiST.
Treatment and dose
Dexamethasone is administered in four doses of 6mg
at 12-h intervals, whereas b-methasone is adminis-
tered as two doses of 12mg at 12-h interval.
15 Most
of the RCTs (14 studies) involved the administration
of b-methasone. Six of the previous stud-
ies
21,23,30,31,33,34 used dexamethasone. According to a
Cochrane review, b-methasone resulted in a greater
reduction in RDS (RR¼0.56; 95% CI 0.48–0.65; 14
studies; 2563 infants) than dexamethasone treatment
(RR¼0.80; 95% CI 0.68–0.93; six studies; 1457
infants).
10 In addition, b-methasone did not increase
puerperal sepsis; whereas dexamethasone was asso-
ciated with a significant increase (RR¼1.74; 95% CI
1.04–2.89; four studies; 536 women).
10 However,
another Cochrane review in the same year concluded
that dexamethasone was associated with not only a
higher rate of NICU admission but also a lower inci-
dence of intraventricular haemorrhage compared with
b-methasone (RR¼0.44; 95% CI 0.21–0.92; four stu-
dies; 549 infants).
40 More trials of commonly used
corticosteroids are required in order to make definitive
recommendations on the choice of steroid.
Timing of doses
Antenatal steroids administration appears to be
effective when there is birth within 24 or 48h of
treatment, if there is birth in 47 days after treatment
(RR¼1.45; 95% CI 0.75–2.8; 561 babies). This may
reflect the increasing maturity of such babies.
26
Number of doses
In 18 RCTs examined, eight had a protocol for a
repeated course of treatment each week until
birth. In their study, comparing repeated steroid
doses to women at risk of preterm labour, Crowther
et al.
41 found that babies born to women who had
received repeat corticosteroids were less likely to
have respiratory problems after birth. In addition,
babies that did develop respiratory problems had
less severe episodes and lower requirement for venti-
lation.
41 However, the benefit of a single and/or
incomplete dose of antenatal corticosteroids on mor-
tality and morbidity related to preterm infants is
clear.
42,43
Effects of the intervention on neonatal
deaths due to direct complications of
preterm birth
In the Cochrane review, 18 studies with mortality out-
comes involving 3956 infants were included.
10
Antenatal steroid treatment was associated with
reductions in neonatal mortality in very preterm
babies (RR¼0.69; 95% CI 0.58–0.81; 18 studies;
3956 babies) and morbidity (RDS) (RR¼0.66; 95%
CI 0.59–0.73; 21 studies; 4038 babies). No evidence
of effects on maternal mortality or stillbirths were
identified.
10 No long-term complications were
observed for surviving children—indeed there were
non-significant trends towards reduced cerebral
palsy and visual impairment following treatment
with antenatal steroids. A sensitivity meta-analysis
of the Cochrane review, but with two excluded stu-
dies,
36,37 also showed an association between antena-
tal steroid treatment and a reduction in neonatal
mortality among very preterm babies (RR¼0.66;
95% CI 0.56–0.78; 20 studies; 4143 babies).
Of the 18 studies with mortality outcomes, 14 are
from HICs with current neonatal mortality rates
(NMR) of less than 5 per 1000 and universal coverage
of intensive care with ventilation for all babies and
surfactant for all babies since mid-1990s. In contrast,
in sub-Saharan Africa, the average NMR is 30 per
1000. Hence, the generalizability of these results to
low- and middle-income countries is unclear. The
mortality effect estimated by the Cochrane review
might substantially underestimate the effect that
could be expected in a setting in which preterm new-
borns currently receive little or no basic neonatal
medical care, let alone intensive care.
Variation of mortality effect size in the pre-surfactant
era and during testing and post-surfactant era
We, therefore, hypothesized that earlier studies, in
which the control groups received no surfactant and
less complex intensive care and thus more closely
resemble current conditions in low- and
middle-income countries, might report larger effects
than more recent studies. Reordering the 18 studies
in the Cochrane review by date, instead of author
names in alphabetical order, does not reveal a clear
trend, with relatively large effects seen in the four
most recent studies (Figure 3). However, the last
four studies were from middle-income countries and
so may confound any time trend in high-income
countries. After excluding these four studies, there
was no evidence of a time trend in the effect of ster-
oids (P¼0.9). We undertook sub-analyses to see if
earlier studies in the pre-surfactant era, and when
intensive care was less complex, would indicate a
greater effect size that may be more applicable for
current low-income country settings (meta-analysis
not shown). As the first surfactant trial was in
Japan in 1980,
44,45 we defined the pre-surfactant era
as pre-1980 (RR¼0.71; 95% CI 0.54–0.93; five
i126 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYstudies; 1615 babies), the surfactant testing era from
1980 to 1990 (RR¼0.94; 95% CI 0.66–1.33; five stu-
dies; 1245 babies) and the post-surfactant era after
1991, excluding MICs (RR¼0.80; 95% CI 0.48–1.35;
four studies; 425 babies). There is no evidence that
the mortality effect varied across these three periods
(P¼0.50). It is interesting to note that new studies
were not instituted in HICs after the NIH Consensus
statement on antenatal steroid use.
15
Variation of mortality effect size in low- and
middle-income countries
We then performed a separate meta-analysis
restricted to four RCTs from middle-income countries
(Table 1). There is evidence (P¼0.008) of a larger
reduction in neonatal mortality in middle-income set-
tings (Figure 4a; RR¼0.47; 95% CI 0.35–0.64; four
studies; 672 babies) than in high-income settings
(Figure 5; RR¼0.79; 95% CI 0.65–0.96; 14 studies;
3284 babies).
10A meta-analysis (Figure 4b) of mor-
bidity (RDS) in middle-income countries produces
an effect estimate (RR¼0.63; 95% CI 0.49–0.81;
four studies; 668 babies) similar to the effect estimate
reported by the Cochrane review (RR¼0.66; 95% CI
0.59–0.73; 21 studies; 4038 babies).
Finally, we undertook a meta-analysis of the two
identified observational studies from middle-income
countries, which gave a summary risk ratio of 0.55
(95% CI 0.40–0.76) for mortality (Figure 6).
Overview of the findings and the quality
of evidence
In summary, there is high-quality evidence of a sub-
stantial mortality effect of antenatal steroids, and this
effect is greater in MICs than in high-income settings
(Table 2). However, there is a dearth of data from
low-income countries (Box 1).
Discussion
Preterm birth is the leading cause of neonatal mortal-
ity and morbidity in both high- and low-income
countries. The recent Cochrane review shows very
substantial benefit of antenatal steroid therapy on
preterm neonatal mortality (31%) and morbidity out-
comes (34% reduction in RDS). Our meta-analysis,
restricted to four RCTs from middle-income countries,
suggests an even larger effect: namely a halving of
deaths due to complications of preterm birth (53%
reduction with a CI of 36–65%). Given that there
are 41 million preterm deaths each year,
1 most of
whom do not currently benefit from antenatal ster-
oids, this intervention has the potential to prevent up
to 500000 neonatal deaths each year.
Risk ratio
.1 1 10
Study
 % Weight
 Risk ratio
 (95% CI)
 0.87 (0.63,1.19)  Liggins 1972  24.3
 0.19 (0.02,1.54)  Block 1977   1.8
 1.02 (0.43,2.41)  Taeusch 1979   3.0
 0.27 (0.09,0.81)  Doran 1980   4.3
 0.23 (0.07,0.79)  Schutte 1980   4.2
 1.06 (0.67,1.68)  Collaborative 1981  10.9
 1.00 (0.07,15.00)  Nelson 1985   0.3
 0.32 (0.01,7.45)  Parsons 1988   0.5
 0.84 (0.43,1.63)  Gamsu 1989   5.8
 0.78 (0.30,2.06)  Morales 1989   2.9
 0.99 (0.47,2.10)  Garite 1992   3.4
 0.64 (0.19,2.21)  Kari 1994   2.1
 1.03 (0.07,15.82)  Lewis 1996   0.3
 0.68 (0.27,1.73)  Silver 1995   3.1
 0.50 (0.28,0.89)  Amorim 1999   9.6
 0.48 (0.15,1.55)  Dexiprom 1999   2.8
 0.45 (0.29,0.70)  Qublan 2001  13.8
 0.46 (0.23,0.93)  Fekih 2002   6.9
 0.69 (0.58,0.81)  Overall (95% CI)
Figure 3 A meta-analysis (fixed effects) of 18 RCTs comparing administration of antenatal steroids for preterm labour with
placebo and showing effect on preterm cause-specific mortality outcome. Total events¼491; heterogeneity 
2¼21.54
(df¼17); P¼0.203; test of RR¼1; z¼4.50; P¼0.000. Fixed effect meta-analysis. Note: 18 RCTs the same inputs as
Cochrane review
10 but meta-analysis revised to order by date of study instead of author alphabetical order
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.1 1 10
Study  % Weight
 Risk ratio
 (95% CI)
 0.50 (0.28,0.89)  Amorium 1999  28.9
 0.48 (0.15,1.55)  Dexiprom 1999   8.4
 0.45 (0.29,0.70)  Qublan 2001  41.8
 0.46 (0.23,0.93)  Fekih 2002  20.9
 0.47 (0.35,0.64)  Overall (95% CI)
Risk ratio
.1 1 10
Study  % Weight
 Risk ratio
 (95% CI)
 1.16 (0.75,1.79)  Dexiprom 1999  24.0
 0.53 (0.35,0.82)  Amorium 1999  37.9
 0.54 (0.31,0.95)  Qublan 2001  21.9
 0.17 (0.05,0.55)  Fekih 2002  16.1
 0.63 (0.49,0.81)  Overall (95% CI)
(a)
(b)
Figure 4 Meta-analysis of four RCTs from middle-income countries comparing administration of antenatal steroids for
preterm labour with placebo: (a) effect size on preterm cause-specific mortality outcome [total events¼142; heterogeneity

2¼0.08 (d.f.¼3); P¼0.994; test of RR¼1; z¼4.87; P¼0.000; fixed effect meta-analysis]; and (b) effect size on RDS
(severe morbidity outcome) [total events¼185; heterogeneity 
2¼13.40 (d.f.¼3); P¼0.004; test of RR¼1; z¼3.58;
P¼0.000; random effects meta-analysis]
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.1 1 10
Study  % Weight
 Risk ratio
 (95% CI)
 0.61 (0.43,0.85)  Meneguel 2003  76.0
 0.39 (0.18,0.84)  Nayeri 2005  24.0
 0.55 (0.40,0.76)  Overall (95% CI)
Figure 6 Fixed effect meta-analysis of two observational studies from low/middle-income countries comparing adminis-
tration of antenatal steroids for preterm labour with placebo showing effect size on neonatal mortality outcome. Total
events¼135; fixed effect meta-analysis; heterogeneity 
2¼1.09 (df¼1); P¼0.297; test of RR¼1; z¼3.70; P¼0.000
Risk ratio
.1 1 10
Study  % Weight
 Risk ratio
 (95% CI)
 0.19 (0.02,1.54)  Block 1977   2.6
 1.06 (0.67,1.68)  Collaborative 1981  16.3
 0.27 (0.09,0.81)  Doran 1980   6.4
 0.84 (0.43,1.63)  Gamsu 1989   8.6
 0.99 (0.47,2.10)  Garite 1992   5.1
 0.64 (0.19,2.21)  Kari 1994   3.1
 1.03 (0.07,15.82)  Lewis 1996   0.5
 0.87 (0.63,1.19)  Liggins 1972  36.3
 0.78 (0.30,2.06)  Morales 1989   4.3
 1.00 (0.07,15.00)  Nelson 1985   0.5
 0.32 (0.01,7.45)  Parsons 1988   0.8
 0.23 (0.07,0.79)  Schutte 1980   6.3
 0.68 (0.27,1.73)  Silver 1996   4.6
 1.02 (0.43,2.41)  Taeusch 1979   4.5
 0.79 (0.65,0.96)  Overall (95% CI)
Figure 5 Fixed effects meta-analysis of 14 RCTs from high-income countries comparing administration of antenatal
steroids for preterm labour with placebo showing effect size on neonatal mortality outcome. Total events¼349; fixed effect
meta-analysis; heterogeneity 
2¼12.48 (df¼13); P¼0.489; test of RR¼1; z¼2.33; P¼0.020
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i130 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYThe clearest evidence for an effect is for babies born
between 31 weeks and 36 weeks gestation but, sur-
prisingly, there may be benefit at even lower gesta-
tional ages, although it should be noted that in all
these studies mechanical ventilation was routinely
available in addition to antenatal steroids (Figure 1).
Importantly, the trials from settings with neonatal
intensive care may underestimate the effect in
low-income countries where there is little or no care
for preterm neonates because neonatal intensive care
was standard practice for the control group in all
these trials (Box 1). Even if only one dose is given
<24h before birth, the effect is high at 47% reduc-
tion.
10 The benefits of corticosteroids given to women
with preterm premature rupture of membranes have
also been demonstrated, lessening the rate of bronch-
opulmonary dysplasia in the offspring of these
women.
46 Use of surfactant along with corticosteroid
administration may enhance the benefits,
47 although
the large trial size required to prove synergy means
that this has not yet been convincingly demonstrated.
The quality of estimate has a high evidence grade
given the four RCTs from the middle-income coun-
tries and a large and consistent effect size.
Considerably, more than 50 deaths are included in
all these analysis. The searches and abstraction of
studies for this review were done by one author and
checked by another author. We acknowledge this as a
limitation compared with double abstraction. The
generalizability is moderate because there are no
RCTs reported from low-income countries or any
from South Asia.
There has been some uptake of antenatal steroid
therapy in middle-income countries such as South
Africa
33 and Thailand.
48 However, the mean coverage
in 75 countries with 490% of maternal, newborn and
child deaths was estimated at around only 10%.
49
Even in middle-income countries, antenatal steroids
may not be routinely administered. For example, in
22 hospitals in Mexico City and 18 in the Northeast
region of Thailand, <20% of those indicated to receive
antenatal steroids did so.
50
Conclusions
Based on the Cochrane
10 review and additional
meta-analyses for middle-income countries, there is
high grade evidence that antenatal steroids are extre-
mely effective in reducing deaths from direct compli-
cations of preterm birth. An injection to a woman in
preterm labour of a drug that costs several dollars
should be highly cost-effective as well as feasible.
In addition, there are minimal if at all any adverse
effects on the mother, fetus or child.
10 While this
intervention has played a major role in altering
the profile of complications for preterm babies in
high-income countries, in low-income countries
where preterm labour is more common and where
care for preterm babies is largely lacking, the use of
antenatal steroids remains a missed opportunity in
many facility births and a total gap for 60 million
births outside facilities each year.
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Box 1: Key messages for the cause-specific
mortality effect and quality grade for the effect of
antenatal steroids given to women in preterm
labour
Cause-specific mortality to act on: preterm
direct complications (within neonatal period).
Cause-specific effect and range:
53% (36–65%) based on four RCT meta-analysis.
Consistent with meta-analysis of two observa-
tional studies from middle-income countries
(45%, 24–68%).
Quality of input evidence:
High, given 18 RCTs in Cochrane and four RCTs in
low/middle-income countries. Mortality and mor-
bidity data consistent. Observational study mortal-
ity data also consistent.
Proximity of the data to cause-specific mortality
effect: high (cause-specific mortality).
Limitations:
The control group in all these studies was routine
care, including ventilation and in many cases sur-
factant. In low-income countries, many preterm
babies currently receive little or no medical care.
It is plausible that the effect of antenatal steroids
may be even greater than that estimated above in
settings where little other care is available.
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